Nissui Pharmaceutical Co., Ltd.
Nissui Pharmaceutical Co., Ltd. Fundamental Analysis
Nissui Pharmaceutical Co., Ltd. (4550.T) shows moderate financial fundamentals with a PE ratio of 25.12, profit margin of 1.27%, and ROE of 65.25%. The company generates N/A in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 86.7/100 based on profitability, valuation, growth, and balance sheet metrics. The B+ grade reflects solid fundamentals with room for improvement in valuation or growth.
Fundamental Health Score
We analyze 4550.T's fundamental strength across five key dimensions:
Efficiency Score
Excellent4550.T demonstrates superior asset utilization.
Valuation Score
Moderate4550.T shows balanced valuation metrics.
Growth Score
Moderate4550.T shows steady but slowing expansion.
Financial Health Score
Excellent4550.T maintains a strong and stable balance sheet.
Profitability Score
Weak4550.T struggles to sustain strong margins.
Key Financial Metrics
Is 4550.T Expensive or Cheap?
P/E Ratio
4550.T trades at 25.12 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, 4550.T's PEG of 0.25 indicates potential undervaluation.
Price to Book
The market values Nissui Pharmaceutical Co., Ltd. at 16.36 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at 2.40 times EBITDA. This is generally considered low.
How Well Does 4550.T Make Money?
Net Profit Margin
For every $100 in sales, Nissui Pharmaceutical Co., Ltd. keeps $1.27 as profit after all expenses.
Operating Margin
Core operations generate 10.33 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $65.25 in profit for every $100 of shareholder equity.
ROA
Nissui Pharmaceutical Co., Ltd. generates $57.50 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
FCF Per Share
Each share generates $2.92 in free cash annually.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
25.12
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.25
vs 25 benchmark
P/B Ratio
Price to book value ratio
16.36
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.003
vs 25 benchmark
Current Ratio
Current assets to current liabilities
8.29
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.65
vs 25 benchmark
ROA
Return on assets percentage
0.58
vs 25 benchmark
ROCE
Return on capital employed
0.05
vs 25 benchmark
How 4550.T Stacks Against Its Sector Peers
| Metric | 4550.T Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 25.12 | 28.25 | Better (Cheaper) |
| ROE | 65.25% | 780.00% | Weak |
| Net Margin | 127.47% | -20122.00% (disorted) | Strong |
| Debt/Equity | 0.00 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 8.29 | 4.66 | Strong Liquidity |
| ROA | 57.50% | -14687.00% (disorted) | Strong |
4550.T outperforms its industry in 5 out of 6 key metrics, particularly excelling in Net Margin, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Nissui Pharmaceutical Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation